Table 4 Coagulation parameters mean values for healthy Beagle dogs treated with enflicoxib orally once a week for up to 7 months (SD)
Treatment group | 0X | 1X | 3X | 5X | ||
|---|---|---|---|---|---|---|
Dose (loading+maintenance) | (Placebo) | (8 + 4 mg/kg) | (24 + 12 mg/kg) | (40 + 20 mg/kg) | Pa | |
Prothrombin time (sec) (PT) | Basal | 8,01 (0,35) | 7,85 (0,53) | 7,65 (0,39) | 7,73 (0,34) | ns |
Week 4 | 8,13 (0,48) | 7,89 (0,58) | 7,65 (0,57) | 7,68 (0,45) | ns | |
Week 8 | 8,28 (0,35) | 8,38 (0,57) | 7,96 (0,52) | 7,84 (0,40) | ns | |
Week 13 | 8,15 (0,39) | 8,05 (0,43) | 7,68 (0,39) | 7,78 (0,36) | ns | |
Week 17 | 8,03 (0,44) | 7,99 (0,60) | 7,84 (0,68) | ns | ||
Week 21 | 8,26 (0,40) | 8,16 (0,46) | 7,99 (0,65) | ns | ||
Week 25 | 8,38 (0,42) | 8,24 (0,41) | 7,78 (0,49) | ns | ||
Week 30 | 8,04 (0,23) | 7,98 (0,41) | 7,61 (0,38) | ns | ||
Activated partial thromboplastin time (sec) (APTT) | Basal | 16,1 (1,0) | 15,7 (1,4) | 16,2 (0,9) | 16,0 (0,9) | ns |
Week 4 | 15,6 (0,9) | 15,5 (0,7) | 15,6 (0,5) | 15,3 (0,8) | ns | |
Week 8 | 16,0 (0,8) | 15,6 (0,6) | 15,7 (0,6) | 15,5 (1,0) | ns | |
Week 13 | 15,8 (0,6) | 15,3 (0,7) | 15,1 (0,2) | 14,9 (0,8) | ns | |
Week 17 | 15,3 (1,0) | 15,1 (0,9) | 15,3 (1,0) | ns | ||
Week 21 | 15,4 (0,6) | 14,9 (0,8) | 15,2 (0,4) | ns | ||
Week 25 | 15,6 (0,7) | 15,1 (0,7) | 15,2 (0,3) | ns | ||
Week 30 | 15,0 (0,6) | 14,6 (0,4) | 14,7 (0,3) | ns | ||
Fibrinogen concentration (g/L) (Fib) | Basal | 2,43 (0,76) | 2,10 (0,46) | 2,26 (0,61) | 1,96 (0,27) | ns |
Week 4 | 2,22 (0,54) | 1,95 (0,52) | 2,06 (0,43) | 1,77 (0,44) | ns | |
Week 8 | 2,09 (0,59) | 1,91 (0,51) | 1,85 (0,24) | 2,56 (0,75) | ns | |
Week 13 | 1,97 (0,41) | 1,93 (0,19) | 2,02 (0,22) | 1,72 (0,25) | ns | |
Week 17 | 2,01 (0,39) | 1,90 (0,26) | 1,91 (0,26) | ns | ||
Week 21 | 2,40 (0,47) | 2,19 (0,27) | 2,09 (0,31) | ns | ||
Week 25 | 2,20 (0,36) | 2,03 (0,19) | 1,89 (0,35) | ns | ||
Week 30 | 1,90 (0,48) | 1,93 (0,20) | 2,15 (0,63) | ns |